The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: HD17 for Intermediate Stage Hodgkin Lymphoma
Official Title: HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma
Study ID: NCT01356680
Brief Summary: This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
1st Dept. of Medicine, Cologne University Hospital, Cologne, , Germany
Name: Andreas Engert, Prof.
Affiliation: University of Cologne, German Hodgkin Study Group
Role: PRINCIPAL_INVESTIGATOR